share_log

Panbela Therapeutics | CORRESP: CORRESP

SEC announcement ·  Jan 26 00:43
Summary by Futu AI
Panbela Therapeutics, Inc., represented by ROTH CAPITAL PARTNERS, LLC, has formally requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-1 effective at 5:30 p.m. Eastern time on January 25, 2024. This request, made under Rule 461 of the Securities Act of 1933, aims for the Registration Statement to be effective as soon as possible after the specified time. Additionally, in compliance with Rule 460, ROTH CAPITAL PARTNERS has distributed the Preliminary Prospectus dated January 25, 2024, to ensure adequate distribution. The placement agent also confirms adherence to Rule 15c2-8 under the Securities Exchange Act of 1934.
Panbela Therapeutics, Inc., represented by ROTH CAPITAL PARTNERS, LLC, has formally requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-1 effective at 5:30 p.m. Eastern time on January 25, 2024. This request, made under Rule 461 of the Securities Act of 1933, aims for the Registration Statement to be effective as soon as possible after the specified time. Additionally, in compliance with Rule 460, ROTH CAPITAL PARTNERS has distributed the Preliminary Prospectus dated January 25, 2024, to ensure adequate distribution. The placement agent also confirms adherence to Rule 15c2-8 under the Securities Exchange Act of 1934.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.